Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

781
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
781
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

647
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
647
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.5K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Human Pharmacogenomics Approach Provides Insight Into the Pathogenesis and Pathophysiology of Steroid-Induced Ocular Hypertension.

Ophthalmology science·2026
Same author

Mental health disorders following nephrectomy for renal cell carcinoma: a national study.

BJU international·2026
Same author

Sarcopenia is associated with poor survival among patients with non-metastatic renal cell carcinoma and venous tumor thrombus.

World journal of urology·2026
Same author

How does maternal "belief in a dangerous world" affect maternal and child depressive symptoms during times of crisis?

Journal of affective disorders reports·2026
Same author

Abdominal fat distribution phenotypes and metabolic risk in premenopausal Asian women: insights beyond general adiposity measures.

Scientific reports·2026
Same author

Making Sense of Mollicute Screening in Lung Transplant Recipients: Challenges and Opportunities.

Transplant infectious disease : an official journal of the Transplantation Society·2026

Related Experiment Video

Updated: Apr 13, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K

C-reactive protein in urologic cancers.

Jonathan Huang1, Yoram Baum1, Mehrdad Alemozaffar1

  • 1Department of Urology, Emory University, Atlanta, USA.

Molecular Aspects of Medicine
|May 5, 2015
PubMed
Summary

C-reactive protein (CRP) levels indicate disease status in many urologic cancers. Understanding CRP in urologic cancers aids treatment decisions and improves patient outcomes.

Keywords:
Bladder cancerC-reactive proteinPenile cancerProstate cancerRenal cell carcinomaTesticular cancerUpper tract urothelial cancer

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

10.0K

Related Experiment Videos

Last Updated: Apr 13, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

10.0K

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • C-reactive protein (CRP) is an acute-phase reactant indicating inflammation, infection, or malignancy.
  • Urologic cancers are known to influence CRP levels, impacting disease characteristics and patient prognosis.
  • CRP is integrated into survival nomograms for several urologic cancers to enhance predictive accuracy.

Purpose of the Study:

  • To explore the role of C-reactive protein (CRP) in various urologic cancers.
  • To investigate the prognostic value of pre-treatment and post-treatment CRP levels.
  • To understand the potential correlation between CRP and treatment side effects in testicular cancer.

Main Methods:

  • Review of existing literature on C-reactive protein (CRP) and urologic malignancies.
  • Analysis of studies correlating pre-treatment CRP serum levels with disease characteristics and survival.
  • Examination of studies on post-treatment CRP levels and their impact on patient survival.

Main Results:

  • Pre-treatment CRP levels predict disease characteristics, extent, and survival in renal cell carcinoma, prostate cancer, bladder cancer, upper tract urothelial carcinoma, and penile cancer.
  • Post-treatment CRP levels show promise in determining survival outcomes.
  • The association between CRP and survival in testicular cancer requires further investigation, though elevated levels may relate to side effects like cardiovascular disease and fatigue.

Conclusions:

  • C-reactive protein (CRP) serves as a valuable biomarker in managing urologic cancers.
  • CRP levels offer predictive insights into disease progression and patient survival.
  • Further research into CRP's role in testicular cancer and treatment side effects is warranted to optimize patient care.